首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Hepatotoxic effect of Rifampicin as an Anti-Tuberculosis drug on male Albino rat
【24h】

Hepatotoxic effect of Rifampicin as an Anti-Tuberculosis drug on male Albino rat

机译:利福平作为抗结核药物对雄性白化病大鼠的肝毒性作用

获取原文
           

摘要

Tuberculosis is one of the serious airborne infectious diseases. Rifampicin is commonly used as anti-tuberculosis drug which creates drug-induced hepatotoxicity. Physiologically, liver maintains metabolic homeostasis and also regulates the detoxification process. The study of rifampicin mediated hepatotoxicity had been performed on male albino rat after its oral administration with a dose of 50 mg/kg body weight/day for 14 days. Several biochemical markers like serum glutamate pyruvate tranaminase (AST), serum glutamate oxaloacetate transaminase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), serum total protein, serum bilirubin, serum cholesterol were considered to evaluate the toxicity. Significant elevation of level of AST (115.89%), ALT (134.40%), ALP (46.15%), serum cholesterol (91%) and bilirubin content (119.44%) had been observed in treated group compared with control group. High level of MDA content as lipid peroxidation marker was also been noticed in drug induced group. Histopathological studies had shown the disintegrated hepatolobular structure with dilated central vein. All these findings indicated that the selected dose of rifampicin is hepatotoxic; proper monitoring and care are essential during the treatment of tuberculosis.
机译:结核病是严重的空气传播传染病之一。利福平通常用作抗结核药,可产生药物诱导的肝毒性。在生理上,肝脏维持新陈代谢的稳态,并调节排毒过程。在雄性白化病大鼠口服剂量为50 mg / kg体重/天的14天后,已经进行了利福平介导的肝毒性研究。考虑了几种生化标志物,如血清谷氨酸丙酮酸转氨酶(AST),血清谷氨酸草酰乙酸转氨酶(ALT),碱性磷酸酶(ALP),乳酸脱氢酶(LDH),血清总蛋白,血清胆红素,血清胆固醇,以评估毒性。与对照组相比,治疗组的AST(115.89%),ALT(134.40%),ALP(46.15%),血清胆固醇(91%)和胆红素含量(119.44%)显着升高。在药物诱导组中也注意到高水平的MDA含量作为脂质过氧化标记。组织病理学研究显示肝小球结构破裂,中心静脉扩张。所有这些发现表明,选定剂量的利福平具有肝毒性。在结核病的治疗过程中,适当的监视和护理至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号